Search Results for: Diabetes

3097 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
INSR and PTPN2 insulin receptor protein tyrosine phosphatase, non-receptor type 2
  • Insulin receptor signalling cascade
  • IRS activation
  • Signal attenuation
  • IRS-related events
  • SHC-related events
  • Insulin receptor recycling
  • SHC activation
  • Signaling by Insulin receptor
  • Insulin Regular
  • Insulin Lispro
  • Insulin Glargine
  • Insulin, porcine
  • Mecasermin
  • Insulin Aspart
  • Insulin Detemir
  • Insulin Glulisine
  • Adenosine-5\'-[Beta, Gamma-Methylene]Triphosphate
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • Insulin, isophane
IRS1 and PRKCQ insulin receptor substrate 1 protein kinase C, theta
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • PI-3K cascade
  • SOS-mediated signalling
  • PI3K Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Adaptive Immune System
  • IRS-mediated signalling
  • PIP3 activates AKT signaling
  • IGF1R signaling cascade
  • IRS-related events triggered by IGF1R
  • IRS activation
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • IRS-mediated signalling
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • PI3K Cascade
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
KCNJ11 and ABCC8 potassium channel, inwardly rectifying subfamily J, member 11 ATP-binding cassette, sub-family C (CFTR/MRP), member 8
  • Inwardly rectifying K+ channels
  • Integration of energy metabolism
  • ATP sensitive Potassium channels
  • Regulation of insulin secretion
  • Potassium Channels
  • Inwardly rectifying K+ channels
  • ABC-family proteins mediated transport
  • Integration of energy metabolism
  • ATP sensitive Potassium channels
  • Regulation of insulin secretion
  • Potassium Channels
  • Glimepiride
  • Ibutilide
  • Verapamil
  • Levosimendan
  • Glyburide
  • Diazoxide
  • Thiamylal
  • Adenosine triphosphate
  • Glimepiride
  • Chlorpropamide
  • Nateglinide
  • Repaglinide
  • Glyburide
  • Glipizide
  • Gliclazide
  • Tolbutamide
  • Gliquidone
  • Mitiglinide
  • Glycodiazine
KIF11 and PPARG kinesin family member 11 peroxisome proliferator-activated receptor gamma
  • MHC class II antigen presentation
  • Kinesins
  • Factors involved in megakaryocyte development and platelet production
  • Adaptive Immune System
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Adenosine-5\'-Diphosphate
  • 3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol
  • Monastrol
  • (4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE
  • N,N-DIETHYL-2-[(2-THIENYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE
  • (5R)-N,N-DIETHYL-5-METHYL-2-[(THIOPHEN-2-YLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE
  • (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide
  • [(4R)-4-(3-HYDROXYPHENYL)-1,6-DIMETHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL](PHENYL)METHANONE
  • (2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE
  • (1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE
  • (2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE
  • (5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
NOTCH2 and DLL1 notch 2 delta-like 1 (Drosophila)
  • Notch-HLH transcription pathway
  • Signaling by NOTCH2
  • Generic Transcription Pathway
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Transcription and Translation
  • Signaling by NOTCH
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Expression and Processing
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Signaling by NOTCH4
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Constitutive Signaling by NOTCH1 HD Domain Mutants
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Signaling by NOTCH3
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
PTPN2 and SRC protein tyrosine phosphatase, non-receptor type 2 SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
SRC and HNF1A SRC proto-oncogene, non-receptor tyrosine kinase HNF1 homeobox A
  • Signaling by ERBB2
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
ABL1 and ERBB3 ABL proto-oncogene 1, non-receptor tyrosine kinase erb-b2 receptor tyrosine kinase 3
  • Role of Abl in Robo-Slit signaling
  • CDO in myogenesis
  • Axon guidance
  • Myogenesis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Signaling by Robo receptor
  • Regulation of actin dynamics for phagocytic cup formation
  • Innate Immune System
  • Adenosine triphosphate
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • MYRISTIC ACID
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
ABL2 and ERBB3 ABL proto-oncogene 2, non-receptor tyrosine kinase erb-b2 receptor tyrosine kinase 3
  • Role of Abl in Robo-Slit signaling
  • Axon guidance
  • Signaling by Robo receptor
  • Adenosine triphosphate
  • Dasatinib
  • 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
ACHE and LAMA1 acetylcholinesterase (Yt blood group) laminin, alpha 1
  • Synthesis of PC
  • Peptide hormone metabolism
  • Synthesis, secretion, and deacylation of Ghrelin
  • Metabolism of lipids and lipoproteins
  • Neurotransmitter Clearance In The Synaptic Cleft
  • Phospholipid metabolism
  • Glycerophospholipid biosynthesis
  • Transmission across Chemical Synapses
  • Axon guidance
  • Laminin interactions
  • ECM proteoglycans
  • L1CAM interactions
  • Non-integrin membrane-ECM interactions
  • Choline
  • Tacrine
  • Gallamine Triethiodide
  • Pyridostigmine
  • Galantamine
  • Isoflurophate
  • Pralidoxime
  • Minaprine
  • Donepezil
  • Demecarium
  • Physostigmine
  • Rivastigmine
  • Edrophonium
  • Ambenonium
  • Tubocurarine
  • Decamethonium
  • Ephedrine
  • Neostigmine
  • Monoisopropylphosphorylserine
  • Huperaine A
  • Propidium
  • 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium
  • 3,6,9,12,15-Pentaoxaheptadecane
  • 1-Deoxy-1-Thio-Heptaethylene Glycol
  • (4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium
  • Methylphosphonic Acid Ester Group
  • Methylphosphinic Acid
  • 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium
  • Acetylcholine
  • beta-L-fucose
  • M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene
  • 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose
  • 2-(N-Morpholino)-Ethanesulfonic Acid
  • MF268
  • 3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine
  • 3-[(1s)-1-(Dimethylamino)Ethyl]Phenol
  • (R)-tacrine(10)-hupyridone
  • (S)-tacrine(10)-hupyridone
  • TACRINE(8)-4-AMINOQUINOLINE
  • (9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM
  • 1-(2-nitrophenyl)-2,2,2-trifluoroethyl]-arsenocholine
  • 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE
  • 1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL
  • (1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE
  • 1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE
  • 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM
  • 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE
  • 2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM
ACLY and CDKN2A ATP citrate lyase cyclin-dependent kinase inhibitor 2A
  • Fatty Acyl-CoA Biosynthesis
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Integration of energy metabolism
  • ChREBP activates metabolic gene expression
  • Triglyceride Biosynthesis
  • Cyclin D associated events in G1
  • Oxidative Stress Induced Senescence
  • G1 Phase
  • Cellular Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
  • Oxidative Stress Induced Senescence
  • Cellular Senescence
  • Oncogene Induced Senescence
ACTB and CDKN2A actin, beta cyclin-dependent kinase inhibitor 2A
  • Axon guidance
  • Gap junction degradation
  • Adherens junctions interactions
  • Translocation of GLUT4 to the plasma membrane
  • L1CAM interactions
  • Recycling pathway of L1
  • HATs acetylate histones
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • Interaction between L1 and Ankyrins
  • Cell-cell junction organization
  • EPH-ephrin mediated repulsion of cells
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
  • Gap junction trafficking and regulation
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Regulation of actin dynamics for phagocytic cup formation
  • Folding of actin by CCT/TriC
  • Innate Immune System
  • Cell junction organization
  • Protein folding
  • Formation of annular gap junctions
  • Chromatin organization
  • Gap junction trafficking
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • Signaling by VEGF
  • Chaperonin-mediated protein folding
  • Cell-extracellular matrix interactions
  • Cyclin D associated events in G1
  • Oxidative Stress Induced Senescence
  • G1 Phase
  • Cellular Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
  • Oxidative Stress Induced Senescence
  • Cellular Senescence
  • Oncogene Induced Senescence
ACTG1 and CDKN2A actin gamma 1 cyclin-dependent kinase inhibitor 2A
  • Axon guidance
  • Gap junction degradation
  • Adherens junctions interactions
  • Translocation of GLUT4 to the plasma membrane
  • L1CAM interactions
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • Interaction between L1 and Ankyrins
  • Cell-cell junction organization
  • EPH-ephrin mediated repulsion of cells
  • Gap junction trafficking and regulation
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Regulation of actin dynamics for phagocytic cup formation
  • Innate Immune System
  • Cell junction organization
  • Formation of annular gap junctions
  • Gap junction trafficking
  • Signaling by VEGF
  • Cell-extracellular matrix interactions
  • Cyclin D associated events in G1
  • Oxidative Stress Induced Senescence
  • G1 Phase
  • Cellular Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
  • Oxidative Stress Induced Senescence
  • Cellular Senescence
  • Oncogene Induced Senescence
ACTN4 and CDKN2A actinin, alpha 4 cyclin-dependent kinase inhibitor 2A
  • Response to elevated platelet cytosolic Ca2+
  • Nephrin interactions
  • Platelet degranulation
  • Platelet activation, signaling and aggregation
  • Cyclin D associated events in G1
  • Oxidative Stress Induced Senescence
  • G1 Phase
  • Cellular Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
  • Oxidative Stress Induced Senescence
  • Cellular Senescence
  • Oncogene Induced Senescence
AES and HNF1A amino-terminal enhancer of split HNF1 homeobox A
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by Wnt
  • repression of WNT target genes
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • truncations of AMER1 destabilize the destruction complex
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
JAG1 and NOTCH2 jagged 1 notch 2
  • Signaling by NOTCH4
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Constitutive Signaling by NOTCH1 HD Domain Mutants
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Signaling by NOTCH3
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Notch-HLH transcription pathway
  • Signaling by NOTCH2
  • Generic Transcription Pathway
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Transcription and Translation
  • Signaling by NOTCH
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Expression and Processing
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
AGTR2 and ERBB3 angiotensin II receptor, type 2 erb-b2 receptor tyrosine kinase 3
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • Peptide ligand-binding receptors
  • Class A/1 (Rhodopsin-like receptors)
  • G alpha (i) signalling events
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
NR0B1 and PPARG nuclear receptor subfamily 0, group B, member 1 peroxisome proliferator-activated receptor gamma
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Tretinoin
  • Dexamethasone
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
AKT1 and PRKCQ v-akt murine thymoma viral oncogene homolog 1 protein kinase C, theta
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Activation of BH3-only proteins
  • Signaling by Wnt
  • Platelet Aggregation (Plug Formation)
  • Signaling by EGFRvIII in Cancer
  • AKT phosphorylates targets in the cytosol
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Regulation of beta-cell development
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • DAP12 interactions
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • G-protein beta:gamma signalling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Activation of BAD and translocation to mitochondria
  • Signaling by EGFR
  • GPCR downstream signaling
  • Signaling by VEGF
  • AKT phosphorylates targets in the nucleus
  • Downstream signal transduction
  • Regulation of gene expression in beta cells
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • Translocation of GLUT4 to the plasma membrane
  • deactivation of the beta-catenin transactivating complex
  • VEGFA-VEGFR2 Pathway
  • Metabolism of nitric oxide
  • G beta:gamma signalling through PI3Kgamma
  • PI3K events in ERBB2 signaling
  • VEGFR2 mediated vascular permeability
  • Downstream signaling of activated FGFR
  • Programmed Cell Death
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • eNOS activation and regulation
  • Intrinsic Pathway for Apoptosis
  • Butyrate Response Factor 1 (BRF1) destabilizes mRNA
  • Innate Immune System
  • Signalling by NGF
  • CTLA4 inhibitory signaling
  • AKT-mediated inactivation of FOXO1A
  • Integrin alphaIIb beta3 signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Negative regulation of the PI3K/AKT network
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • eNOS activation
  • TCF dependent signaling in response to WNT
  • KSRP destabilizes mRNA
  • GPVI-mediated activation cascade
  • Signaling by WNT in cancer
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Adenosine triphosphate
  • Arsenic trioxide
  • Inositol 1,3,4,5-Tetrakisphosphate
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine
ALB and HNF1A albumin HNF1 homeobox A
  • Lipoprotein metabolism
  • Bile acid and bile salt metabolism
  • Metabolism of lipids and lipoproteins
  • Recycling of bile acids and salts
  • Platelet degranulation
  • Lipid digestion, mobilization, and transport
  • Transport of organic anions
  • SLC-mediated transmembrane transport
  • HDL-mediated lipid transport
  • Scavenging of heme from plasma
  • Response to elevated platelet cytosolic Ca2+
  • Platelet activation, signaling and aggregation
  • Transport of vitamins, nucleosides, and related molecules
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells

Page 2 out of 155 pages